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Abstract
The main objectives of our study were to determine the bioavailability of omega-3 (ω-3) to the tumor, to understand
its mechanisms, and to determine the feasibility of targeting the ω-6 polyunsaturated fatty acids (PUFAs) metab-
olizing 15-lipoxygenase-1 (15-LO-1) and cyclooxygenase-2 (COX-2) pathways. Nude mice injected subcutaneously
with LAPC-4 prostate cancer cells were randomly divided into three different isocaloric (and same percent [%] of
total fat) diet groups: high ω-6 linoleic acid (LA), high ω-3 stearidonic acid (SDA) PUFAs, and normal (control) diets.
Tumor growth and apoptosis were examined as end points after administration of short-term (5 weeks) ω-3 and
ω-6 fatty acid diets. Tumor tissue membranes were examined for growth, lipids, enzyme activities, apoptosis, and
proliferation. Tumors from the LA diet–fed mice exhibited the most rapid growth compared with tumors from the
control and SDA diet–fed mice. Moreover, a diet switch from LA to SDA caused a dramatic decrease in the growth
of tumors in 5 weeks, whereas tumors grew more aggressively when mice were switched from an SDA to an LA
diet. Evaluating tumor proliferation (Ki-67) and apoptosis (caspase-3) in mice fed the LA and SDA diets suggested
increased percentage proliferation index from the ω-6 diet–fed mice compared with the tumors from the ω-3 SDA-
fed mice. Further, increased apoptosis was observed in tumors from ω-3 SDA diet–fed mice versus tumors from
ω-6 diet–fed mice. Levels of membrane phospholipids of red blood cells reflected dietary changes and correlated
with the levels observed in tumors. Linoleic or arachidonic acid and metabolites (eicosanoid/prostaglandins) were
analyzed for 15-LO-1 and COX-2 activities by high-performance liquid chromatography. We also examined the per-
cent unsaturated or saturated fatty acids in the total phospholipids, PUFA ω-6/ω-3 ratios, and other major enzymes
(elongase, Delta [Δ]-5-desaturase, and Δ-6-desaturase) of ω-6 catabolic pathways from the tumors. We observed a
2.7-fold increase in the ω-6/ω-3 ratio in tumors from LA diet–fed mice and a 4.2-fold decrease in the ratio in tumors
from the SDA diet–fed mice. There was an increased Δ-6-desaturase and Δ-9 desaturase enzyme activities and
reduced estimated Δ-5-desaturase activity in tumors from mice fed the SDA diet. Opposite effects were observed
in tumors from mice fed the LA diet. Together, these observations provide mechanistic roles of ω-3 fatty acids in
slowing prostate cancer growth by altering ω-6/ω-3 ratios through diet and by promoting apoptosis and inhibiting
proliferation in tumors by directly competing with ω-6 fatty acids for 15-LO-1 and COX-2 activities.
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Introduction
Prostate cancer (PCa) still remains one of the leading causes of can-
cer death among men in the United States [1]. Current therapies for
PCa include radical prostatectomy, hormonal therapy, and targeted
radiation. Unfortunately, all available therapies have associated risks
and limitations, and new therapeutic strategies are critically needed
[2,3]. One promising strategy involves the use of dietary interven-
tions [4,5]. International incidence patterns and migration studies,
epidemiological data as well as animal and in vitro studies, indicate
that consuming a diet rich in fat increases the risk for developing
PCa [6–8]. Dietary fat also includes ω-3 and ω-6 polyunsaturated
fatty acids (PUFAs), both of which play important roles in many
human biological processes including PCa [9,10]. Because humans
cannot synthesize ω-3 and ω-6 PUFAs, they are considered essential
fatty acids. Although all mammalian cells can interconvert the PUFAs
within each series by elongation, desaturation, and retroconversion,
the two series are not interchangeable owing to the lack of the Fat-1
gene [11], which encodes the ω-3 desaturase enzyme [12].
Linoleic acid (LA; 18:2ω-6) represents a ω-6 PUFA commonly
found in high-fat Western diets [13]. Terrestrial plants synthesize
LA, and once ingested by mammals, LA is either metabolized to
13-(S )-hydroxyoctadecadienoic acid [13-(S )-HODE] or converted
further to arachidonic acid (AA; 20:4ω-6). Three fatty acids, found
primarily in fish oils, comprise the ω-3 family: alpha linolenic acid
(ALA or α-LNA; 18:3ω-3), eicosapentaenoic acid (EPA; 20:5ω-3),
and docosahexaenoic acid (DHA; 22:6ω-3). ALA, synthesized by
cold-water vegetation, is converted by fish to EPA and DHA. Of
note, through the same series of enzymes used to convert LA to AA,
humans can synthesize EPA and DHA from ingested ALA. The con-
version of dietary ALA to EPA and DHA is also dependent on the
dietary ω-6/ω-3 ratio [13]. Importantly, US diets provide excessive
LA [14] that competes with ALA for the desaturase and elongase
enzymes, impeding the formation of EPA and DHA. Studies have
suggested that the high incidence of PCa in Americans may, in part,
result from an imbalance in the ratio of ω-3 to ω-6 fatty acids because
the typical American diet is low in ω-3 and high in ω-6 [9]. Recently,
we demonstrated increased expression of a ω-6 LA-metabolizing en-
zyme, 15-lipoxygenase-1 (15-LO-1, ALOX15) in prostate tumor tis-
sues compared with normal adjacent tissue [15–17]. Although AA can
also act as a substrate for 15-LO-1, yielding the anti-inflammatory and
proapoptotic metabolite 15-(S)-hydroxyeicosatetraenoic acid [15-(S )-
HETE], the 15-LO-1 enzyme greatly prefers LA. 15-LO-1 metabolizes
LA to 13-(S)-HODE, which can regulate cell growth, differentiation,
and vascular homeostasis [15–17].
In addition, AA also acts as a substrate for cyclooxygenases 1 and 2
(COX-1 and COX-2) [18]. Most tissues constitutively express low pro-
tein levels of COX-1 and no COX-2. Growth factors or inflammatory
agents rapidly induce COX-2 expression in prostate, and studies show
overexpression of COX-2 in PCa [19,20]. COX-2 overexpression,
leading to the production of proinflammatory prostaglandins (e.g.,
PGE2), possibly contributes to PCa pathobiology [21]. Recently, a
study has shown that the combination of DHA and celecoxib
(COX-2–specific inhibitor) prevents PCa cell growth in vitro [22].
This inhibition of disease development likely results, in part, from
the ability of the ω-3 PUFA, EPA, to successfully compete with LA
and AA for 15-LO-1 and COX-2, respectively. 15-LO-1 metabolizes
EPA to 15-hydroxyeicosapentaenoic acid (15-HEPE) [23], a me-
tabolite shown to have antitumorigenic properties, whereas COX-2
metabolizes EPA to the anti-inflammatory and antitumorigenic PGE3
[23,24]. The ω-3 PUFA EPA also serves as a substrate for 15-LO-1 and
COX-2, but metabolism of EPA by these enzymes results in the forma-
tion of antitumorigenic products. Therefore, ω-3 fatty acids may not
only decrease production of the protumorigenic metabolites derived
from the ω-6 fatty acid pathway but also result in increased production
of antitumorigenic metabolites.
On the basis of these and our previous observation [25], we further
hypothesized that prostate tumor growth can be modulated by dietar-
ily targeting the 15-LO-1 and cyclooxygenase (COX)-2 enzymes. This
article describes experiments designed to show that dietarily targeting
the 15-LO-1 and COX-2 enzymes in vivo can slow PCa progression.
Materials and Methods
Cell Culture
Los Angeles Prostate Cancer-4 (LAPC-4) PCa cells were kindly pro-
vided by Dr. Robert Reiter (University of California-Los Angeles) and
maintained in phenol red–free Dulbecco’s modified Eagle medium
(Invitrogen, Carlsbad, CA) containing 5% heat-inactivated fetal calf
serum (Sigma-Aldrich, St. Louis, MO) with streptomycin-penicillin
antibiotics in a 5% CO2 incubator at 37°C.
15-LO-1 and COX Enzyme Activities in Tumors
The activities of 15-LO-1 and COX were estimated as described pre-
viously by us [25]. Briefly, tissue homogenates (total protein, 800 μg)
were incubated with 25 μM [1-14C] AA or [1-14C] LA (1 × 106 cpm;
15 nmol). The reaction mixture (600 μl) contained 50 mM Tris-HCl
(pH 7.4) and 5 mM CaCl2. In all buffers, protease inhibitors were
added just before use: phenylmethylsulfonyl fluoride and benzamidine
at 1 mM each, aprotinin and leupeptin at 10 μg/ml, and pepstatin A
at 1 μg/ml. After the incubation, 0.3 mg of sodium borohydride was
added, and the mixture was kept on ice for 15 minutes. This mix-
ture was then acidified with HCl (pH 3.0). Appropriate unlabeled
eicosanoids were used as internal standards. The sample was extracted
in 2 ml of ethyl ether and solvent-evaporated, and the dried material
was dissolved in 50 μl of methanol/water (3:1) solvent. Reverse-phase
high-performance liquid chromatography (HPLC) analyses was con-
ducted with a C18 Ultra sphere column (5 μm; 4.6 × 250 mm; Altex
Scientific, Beckman Instruments, Fullerton, CA) equipped with a
Waters Model 6000A pump and a Waters Model 717 Autosampler
injector (Milford, MA). Metabolite separation was achieved using a
55% to 100% methanol stepwise gradient at 1.1 ml/min. Eluted ra-
dioactivity was monitored using a Flo-One/Beta detector (Radiomatic
Instruments, Tampa, FL) linked with an IBM Pentium 4 computer
for data processing. UV analysis was also performed (for nonradioac-
tive detection of stearidonic acid (SDA), EPA, and 15-HEPE) bymon-
itoring absorbance at 234 nm with a Waters 486 detector. [1-14C]
Arachidonic acid and [1-14C] LA (40-60 mCi/mmol) were from
DuPont-New England Nuclear (Boston, MA). Unlabeled eicosanoids
such as 13-HODE, 15-HETE, 15-HEPE, and PGs such as PGE2 and
PGE3 were from Cayman Chemical (Ann Arbor, MI). All solvents
were HPLC grade and were from Baker (Phillipsburg, NJ). The
15-LO-1 and COX enzyme activities were expressed as percent con-
version of substrate(s) to product(s).
Enzyme Activity Calculation of Other Enzymes of
Eicosanoids Pathway
The activities of enzymes involved in fatty acid biosynthesis were
estimated as the product-to-precursor ratios of the percentages of
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individual fatty acids [26]. The estimated enzyme activities included
those of elongase, calculated as the stearic acid (18:0)-to-palmitic acid
(16:0) ratio; Δ-5-desaturase, calculated as the AA [20:4(ω-6)]-to-di-
homo-gamma (γ)-linolenic acid (DGLA) [20:3(ω-6)] ratio; Δ-6 de-
saturase, calculated as the DGLA [20:3(ω-6)]-to-LA [18:2(ω-6)]
ratio (assuming that Δ-6 desaturase and not elongase is rate limiting);
and Δ-9 desaturase, calculated as the oleic acid [18:1(ω-9)]-to-stearic
acid [18:0(ω-9)] ratio.
Diets, Experimental Strategy, Feeding Protocol, LAPC-4 Cell
Injection, and Tumor Analyses
We used three different isocaloric diets (caloric density 4.4 kcal/g)
for our study (Table 1). These custom-made, semipurified diets were
prepared and irradiated by Purina Test Diet, Inc. (Richmond, IN).
High ω-6 LA and high ω-3 SDA fat diet groups (experimental) were
identical to those that are described before [25]. Use of pure EPA
is cost-prohibitive, and therefore, SDA, an immediate precursor of
EPA, served as a legitimate substitute. Furthermore, because of con-
cerns with mercury and polychlorinated biphenyl contamination of
fish and fish oils, which currently provide the major sources of long-
chain ω-3 in the human diet, land-based sources of functional ω-3
fatty acids such as SDA are currently being developed [27]. Normal-
fat diet (control) was also isocaloric when adjusted by adding dextrin
and corn oil.
The experimental strategy is illustrated in detail in Figure 2. Ini-
tially, we took a total of 101 athymic male BALB/C nude (nu/nu)
(6-8 weeks old) mice obtained from Charles River (Wilmington,
MA) and fed them initially a no-fat diet for 2 weeks as described
before [25]. As illustrated in Figure 2, after 2 weeks, we split these
mice into three groups, namely, two experimental groups (a total of
n = 76 divided into 38 mice per high ω-6 LA and ω-3 SDA fat diet
groups [experimental]) and a control group [n = 25 per normal die-
tary group]). These mice were housed in single-sterile animal cages to
allow for the maintenance of isocaloric intake between the diet
groups. Cages, bedding, and water were autoclaved before use. Spe-
cially designed feeding receptacles were placed in the cages so that
food intake could be carefully monitored. Sterile techniques were
used whenever handling the cages, mice, and food. The Pittsburgh
Animal Research Committee approved the experiments, and animals
were cared for in accordance with institutional guidelines.
After 2 weeks on no-fat diet, all the n = 101 mice were injected
with LAPC-4 cells. This time point was counted as week 1. The mice
were injected in duplicate subcutaneously in the right and left lateral
flank with 1 × 106 LAPC-4 tumor cells in 0.1 ml of Matrigel (Col-
laborative Biomedical Products, Bedford, MA). When tumors be-
came palpable, the tumor dimensions were measured [28]. Tumor
growth and apoptosis were examined as end points after administra-
tion of different experimental and control short-term (5 week) diets.
At week 23, half of the mice from each PUFA group were switched
to the opposing diets (i.e., from SDA to LA diet and vice versa),
whereas the other half of the mice remained on their original diet.
Tumors were examined for growth, lipids, enzyme activities, apopto-
sis, and proliferation indices.
Red Blood Cells Membrane and Tumor Phospholipid
Content Analyses
Phospholipid content from red blood cells (RBCs) and tumor tis-
sue membranes were analyzed by temperature-programmed micro-
capillary gas liquid chromatography as described before [25]. The
fatty acids are expressed as a percentage from total phospholipids
measured (C14/C22). The interassay coefficient of variation for de-
termining the different fatty acids by this method ranged between
2.6% and 9.1%, reflecting the high reproducibility of the assay.
Assessment of Apoptotic and Proliferation Indices
by Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded LAPC-4 tumor tis-
sues (5 μm) were tested for the presence Ki-67 and caspase-3 (1:50),
using an avidin-biotin complex technique and steam heat–induced
antigen retrieval. Cells were defined as apoptotic if the whole nuclear
area of the cell labeled positively for caspase-3. Apoptotic bodies were
defined as small positively labeled globular bodies in the cytoplasm
of the tumor cells (singly or in groups). To estimate the apoptotic
index (the percentage of apoptotic events in a given area), apoptotic
cells and bodies were counted in 10 high-power fields, and this figure
was divided by the number of tumor cells in the same high-power
fields. We also estimated the apoptotic index by light microscopy
using hematoxylin-stained slides from the same tumor sections as
the caspase-3. The intensity of staining in 10 high-power fields were
scored descriptively or semiquantitatively by a pathologist as 1+ (0%-
25% positive cells), 2+ (25%-50% positive cells), 3+ (50%-75% pos-
itive cells), and ≥4+ (75%-100% positive cells) in a blinded manner.
Proliferation was similarly examined, and index was estimated as total
Ki-67–labeled cells/total cells counted.
Statistical Analyses
Statistical analyses (SAS version 5.0) were performed by Student’s
t test or analysis of variance. Correlations between outcome variables
were computed using the Spearman correlation coefficient. P ≤ .05
was considered significant. Data are expressed as mean ± SD.
Results
Effect of Diets on Tumor Growth
We initially examined the effects of the specific diets (i.e., normal,
ω-3 SDA, and ω-6 LA) on tumor growth (n = 20 mice per diet
group) during a total of a 28-week period (Table 1 and Figure 1).
At week 23, 10 mice from ω-3 SDA diet–fed mice were switched
to ω-6 LA diet and 10 mice from ω-6 LA diet–fed mice were switched
to ω-3 SDA diet. The remaining 10 mice continued to be fed with
Table 1. Composition of Isocaloric Diets (g/100 g).
Ingredients* Normal SDA (ω-3) LA (ω-6)
Sucrose 15.0 35.0 35.0
Casein-vitamin–Free 21.0 21.0 21.0
RP mineral mix no. 10 (adds 1.29% fiber) 5.0 5.0 5.0
Powdered cellulose 3.0 3.0 3.0
RP vitamin mix (adds 1.9% sucrose) 2.0 2.0 2.0
Choline chloride 0.2 0.2 0.2
DL-Methionine 0.2 0.2 0.2
SDA 0.0 15.0 0.0
Safflower oil 0.0 0.0 15.0
Dextrin 38.6 18.6 18.6
Corn oil 5.0 0.0 0.0
Lard 10.0 0.0 0.0
Caloric density is 4.4 kcal/g.
*Values provided by the supplier.
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their original diets. Twenty normal diet–fed mice served as controls.
Tumors from each of these cohorts were measured/week for five more
weeks (i.e., from week 24 to 28). Tumors from the LA diet–fed mice
exhibited the most rapid growth compared with tumors from the
control and SDA diet–fed mice. Moreover, a diet switch from LA to
SDA caused a dramatic decrease in the growth of tumors in 5 weeks
(from week 23 to 28), whereas tumors grew more aggressively when
mice were switched from an SDA to an LA diet in the same period
(Figure 1).
Effect of Diets on Proliferation and Apoptotic Indices
in Tumors
On the basis of the experimental strategy outlined in Figure 2, we
used immunohistochemistry to evaluate tumor proliferation (Ki-67)
and apoptosis’ (caspase-3) in mice (n = 10 per diet groups) fed the
normal, LA, and SDA diets at week 23 (Figure 3A) and week 28
(Figure 3B) time points. As depicted in Figure 3, AX and BX, the
calculated percentage proliferation index was 4-5 ± 0.2-1 in the
SDA diet–fed mice, 7 ± 1-1.5 in the LA diet–fed mice, and 5.8 ±
0.3-0.4 in the normal diet–fed mice. Simultaneously, as depicted
in Figure 3, AY and BY, the calculated percentage apoptotic index
was 1.6-1.7 ± 0.2-0.3 in the SDA diet–fed mice, 0.4 ± 0.1 in the
LA diet–fed mice, and 0.6 ± 0.2-0.1 in the normal diet–fed mice.
As expected, there were no apparent major differences in week 28
versus week 23 in either the proliferation or the apoptosis index.
However, as shown in Figure 3C , we assessed proliferation (X ) and
apoptotic indices (Y ) in tumors after the 5-week period (from week 24
to 28) from diet-switched mice (i.e., from LA to SDA and vice versa,
n = 10 per diet group). We observed a dramatic decrease in the pro-
liferation index and an increase in apoptotic index in tumors from
mice that were switched from LA to SDA diet. Interestingly, these
changes were reversed in tumors from mice that were switched from
SDA to LA diet.
Red Blood Cells and Tumor Phospholipid Content Analyses
As shown in Table 2, A (RBCs) and B (tumors), levels of ω-6 LA,
AA, and ω-3 EPA and DHA in membrane phospholipids of RBCs
reflected dietary changes in normal, LA, and SDA diet–fed mice (n =
10 per diet groups). There were no significant differences in mem-
brane phospholipid content in both these tissues observed at week 23
versus week 28 (a 5-week period). This study also ascertained that the
RBCs membrane phospholipid analysis is suitable for the accurate
Figure 1. Average tumor volumeperweek in experimentalmice. The
tumor dimensions were measured using a caliper. Tumor volumes
were calculated using the formula: length × width × height ×
0.5236 (correction factor). For clarity, the SD error bars from the
mean of 10 values [SD was <10% of the mean] have been omitted.
○: Normal (control) diet–fed mice;▵: LA (ω-6) diet–fed mice;•: SDA(ω-3) diet–fed mice; □: switch from LA to SDA diet; and ♦: switch
from SDA to LA diet.
Figure 2. Experimental strategy.
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Figure 3. Assessment in weeks 23 (A) and 28 (B) of proliferation (X) and apoptotic indices (Y) in tumors from mice fed with SDA ( ), LA ( ),
and normal diets ( ). Similar assessments were performed as shown in diet-switched mice (C) (i.e., from LA to SDA [ ] and vice versa [ ])
after a 5-week period. Sections of formalin-fixed, paraffin-embedded tumor tissues were tested for the presence of Ki-67 (proliferation
marker) and caspase-3 (apoptosis marker). Proliferation and apoptotic indices (%) were estimated as described in the Materials and Meth-
ods section. A total of n = 10 tumor tissues per group were examined.
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measurement of dietary intake of PUFAs. Interestingly, when co-
horts of mice (n = 10) were switched from ω-6 diet to ω-3 diet and
vice versa and allowed to feed further for a 5-week period, the levels of
the ω-6 and ω-3 PUFAs in both RBCs and tumor membrane phos-
pholipids were also modulated accordingly (Table 2, A and B).
Modulation of 15-LO-1, COX, and Key Enzymes of the ω-6
Pathway in Tumors
To assess whether the tumor-modulating effects of ω-3 SDA (anti-
tumorigenic) and ω-6 LA (protumorigenic) diets are suggestive of
their actions in diet-switching experiments, we examined tissue me-
tabolites from different dietary cohorts by HPLC analysis (Table 3).
Tumor lysates from LA diet–fed mice showed two-fold higher levels
of 13-(S )-HODE versus normal diet–fed mice and remained unde-
tectable in SDA diet–fed mice. Interestingly, when cohorts of mice
were switched from ω-6 diet to ω-3 diet (from LA diet to SDA diet),
there was a significant decrease in 13-HODE from 2.1 ± 0.2 to 0.2 ±
0.1 (n = 10, P < .05) and a decrease from 1.8 ± 0.06 to 0.3 ± 0.03
(n = 10, P < .02) in 15-HEPE when cohorts of mice were switched
from ω-3 diet to ω-6 diet (from SDA diet to LA diet). This con-
firmed 15-LO-1 activity in the tumors. Although we did not observe
major differences in the total PG levels in either diet fed or diet
switch groups, formation of PGs confirmed COX activity. We did
not find detectable levels of 15-HETE, indicating either a deficiency
in 15-LO-2 enzyme or a poor 15-LO-1/AA metabolism.
In comparison with mice fed the normal diet, we observed a
2.7-fold increase in the ω-6/ω-3 ratio in tumors from LA-fed mice
and a 4.2-fold decrease in the ratio in tumors from the SDA-fed mice
(Table 4). We observed increased estimated activity of Δ-6-desaturase
enzyme in tumors from mice fed the SDA diet and the decreased
activity in tumors from mice fed the LA diet. Similarly, we observed
a reduced estimated Δ-5-desaturase activity in the tumors from SDA
diet cohort. Interestingly, the estimated activity of the anabolic n-9
monounsaturated fatty acid pathway enzyme, Δ-9-desaturase, in-
creased in tumors from SDA diet–fed mice while it decreased in
tumors from LA diet–fed mice (Table 4).
Discussion
Ideally, the ratio of ω-3 to ω-6 PUFAs in the human body should
be 1:4 to 1:1. A typical US diet is low in ω-3 and high in ω-6, and
many individuals contain 10 to 20 times more ω-6 PUFAs than ω-3
PUFAs and international incidence patterns and migrations studies,
epidemiological data as well as animal and in vitro studies, indicate
that consuming a diet rich in fat increases the risk for developing PCa
[8,29–33].
Our previous in vitro and in vivo studies demonstrate the presence
of ω-6 LA-metabolizing enzyme 15-LO-1 at higher levels in PCa and
as a key enzyme that contributes to the initiation and development of
the neoplastic phenotype in PCa [16,17,25,28,34–36]. In this study,
we provide information on the mechanisms of how the metabolites
of antitumorigenic ω-3 fatty acids can modulate the protumorigenic
ω-6 LA and AA enzymatic pathways.
Our hypothesis was that diet high in ω-3 PUFAs competes with
ω-6 LA and -AA as a substrate for the enzyme 15-LO-1, upregulated
in PCa, resulting in reduced levels of the protumorigenic metabolite
of LA, 13-(S )-HODE, and increased levels of the antitumorigenic
metabolites EPA (SDA metabolite), 15-HEPE, and PGE3. Eicosa-
pentaenoic acid can also compete with AA as a substrate for the
COX-2 enzyme, also upregulated in PCa, resulting in reduced levels
of the proinflammatory metabolite of AA, PGE2, and increased levels
of the anti-inflammatory metabolites of EPA, PGE3. The absence of
detectable 15-HETE indicated either a deficiency in 15-LO-2 en-
zyme or a poor 15-LO-1/AA metabolism [37–39]. Importantly, these
results further corroborate our previous in vitro and in vivo study that
SDA (and EPA) does not inhibit the activities of either 15-LO-1 or
Table 2. Composition of LA, AA, EPA, and DHA in Phospholipids (n = 10).
% of Total Phospholipids Diet Group n = 10
Normal LA Diet SDA Diet ω-6 → ω-3 ω-3 → ω-6
23rd Week 28th Week 23rd Week 28th Week 23rd Week 28th Week 5th Week 5th Week
(A) RBC membranes
LA 6.2 ± 0.6 5.9 ± 0.8 12.2 ± 0.6 11.7 ± 0.6 2.2 ± 0.1 2.4 ± 0.1 3.2 ± 0.6 11.4 ± 0.3
AA 6.3 ± 0.3 6.7 ± 0.4 8.2 ± 0.6 8.4 ± 0.5 6.1 ± 0.1 6.4 ± 0.3 6.4 ± 0.6 7.1 ± 0.7
EPA ND ND ND ND 3.4 ± 0.2 3.2 ± 0.3 3.9 ± 1.2 0.9 ± 0.4
DHA ND ND ND ND 6.2 ± 0.8 5.9 ± 1.2 5.8 ± 1.2 0.4 ± 0.06
(B) Tumors from mice fed with normal, LA, and SDA diets
LA 5.9 ± 0.4 5.8 ± 0.7 12.4 ± 0.4 12.1 ± 0.7 2.5 ± 0.7 2.3 ± 0.9 3.1 ± 0.5 11.8 ± 0.4
AA 6.1 ± 0.3 6.2 ± 0.3 7.8 ± 0.5 7.9 ± 0.7 6.4 ± 0.2 6.1 ± 0.5 6.6 ± 0.8 6.9 ± 0.8
EPA ND ND ND ND 3.3 ± 0.3 3.5 ± 0.1 3.4 ± 0.5 1.1 ± 0.2
DHA ND ND ND ND 6.4 ± 0.4 5.7 ± 0.6 5.9 ± 1.1 0.6 ± 0.04
Fatty acid methyl esters were analyzed by gas liquid chromatography as described in the Materials and Methods section. The fatty acids are expressed as percentage (%) from total phospholipids and
represent the mean ± SD of 10 determinants.
Table 3. Enzyme (15-LO-1 and COX) Activity Profiles from the Tumors of Mice Fed with LA,
SDA, LA to SDA, and SDA to LA Diets Were Measured as Described in the Materials and Meth-
ods Section.
Diet Group at Week 23 (n = 10) Metabolic Products
13-HODE 15-HETE 15-HEPE Total PGs
Normal 0.9 ± 0.2 0.1* 0 6.1 ± 0.33
LA diet 2.1 ± 0.2† ND 0 6.2 ± 0.46
SDA diet ND† ND 1.8 ± 0.06‡ 7.1 ± 0.26
LA to SDA (after a 5-week time point) 0.2 ± 0.1† ND 1.4 ± 0.03‡ 7.6 ± 0.54
SDA to LA (after a 5-week time point) 1.8§ ND 0.3 ± 0.03‡ 6.4 ± 0.22
Percent (%) conversion of the products represents mean ± SD of 10 determinations from one
experiment.
ND indicates not detectable.
*Observed in two tissues.
†P < .05.
‡P < .02.
§Observed in one tissue.
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COX and that tumor growth reflects the substrate competition of
ω-3 with ω-6 fatty acids [25].
The increased estimated activity of Δ-6-desaturase enzyme in
tumors from mice fed the SDA diet and the decreased activity in tu-
mors from mice fed the LA diet could be associated with the accu-
mulation of the antiproliferative GLA and DGLA [40]. Similarly,
reduced estimated Δ-5-desaturase activity in the tumors from SDA
diet cohort confirms the previous observation from in vitro studies with
LAPC-4 cells [25], suggesting that ω-3 SDA inhibits Δ-5-desaturase
enzyme activity. This then further limits the formation of DHA and
causes the accumulation of GLA and DGLA.
The increased estimated activity of the anabolic ω-9 monounsat-
urated fatty acid pathway enzyme, Δ-9-desaturase, in tumors from
SDA diet–fed mice but decreased activity in LA diet–fed mice sug-
gests that SDA can favor the conversion of stearic acid (18:0, n-9) to
oleic acid (18:1, n-9). However, this conversion is inhibited by LA. To-
gether, these observations provide additional support for the role of
ω-3 SDA in slowing PCa growth. The observation of Δ-9-desaturase
activity modulation by SDAmay also suggest that the tumor inhibition
is either independent of oleic acid action [41]. This is particularly an
important consideration for clinical trial studies in PCa patients using
oleic acid as a placebo.
In addition to 15-LO-1, evidence also suggests that other metabolic
enzymes play important roles in PCa pathobiology. Arachidonic acid
obtained through diet or LA metabolic conversion is the preferred sub-
strate for 15-LO-2. 15-LO-2 converts AA to 15-(S)-HETE, a metab-
olite shown to both enhance apoptosis and act as a negative cell cycle
regulator [42]. Furthermore, 15-(S )-HETE has anti-inflammatory
properties [24,43,44], and studies support an association between in-
flammation and PCa [45,46]. Similarly, AA also acts as a substrate for
COX-2 leading to the production of PGs, such as PGE2, that have
proinflammatory effects and thus possibly contribute to PCa pathobi-
ology. Although the present study did not specifically evaluate for both
COX-1 and COX-2 levels or for PGs such as PGE2 versus PGE3, pre-
vious studies have demonstrated an overexpression of COX-2 [19,20]
and an antitumorigenic role of PGE3 in PCa [23,47]. Therefore,
owing to the abundance of COX-2 in PCa tissue, it was reasonable
to assume that most AA in tumors cells would be converted to
PGE2 if ω-3s were low or absent.
More specifically, use of dietary ω-3 PUFAs as agents for cancer
prevention can prove a valuable strategy in the fight against PCa
[48–57] and recurrence. Consequently, 15-LO-1 metabolizes EPA to
15-hydroxyeicosapentaenoic acid [15-HEPE] [47], a metabolite shown
to have antitumorigenic properties, whereas COX-2 that metabolizes
EPA to the anti-inflammatory as well as antitumorigenic PGE3
[23,45,58]. Therefore, based on the substrates, that is, dietary ω-6
or ω-3 in concert with the activities of 15-LO-1 and COXs, cells
can be predisposed to either a proliferative or antiproliferative out-
come. This effect seems to be independent of percent unsaturated
or percent saturated fatty acids in the total phospholipids as observed
in tumors and suggests that the cells are able to maintain membrane
fluidity and functionality of proteins in the membrane.
This study supports our hypothesis and explains the observation
that: 1) EPA and LA both compete as substrates for the enzyme 15-
LO-1, which results in a decrease in the protumorigenic metabolite
of LA, 13-(S )-HODE, and an increase in the antitumorigenic me-
tabolite of EPA, 15-HEPE; and 2) EPA and AA both compete as
substrates for the enzyme COX-2, which may result in the produc-
tion of “good” PGs (for e.g., PGE3). Thus, SDA-derived EPA alone
and EPA-derived fatty acids such as DHA or a combination in fish
oil are promising dietary intervention agents against PCa aimed at
15-LO-1 and COX-2 as the molecular targets.
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